Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine for Impulse Control Disorders in Parkinson's Disease
NCT03146130Phase 3Completed
- Sponsor
- CHU Amiens-Picardie
- Start
- Jan 2019
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of acetylcysteine in impulse control disorder (ICD) (2 arms), sponsored by CHU Amiens-Picardie. Primary endpoint: Variation of the subdivision of the hyperdopaminergic behaviors of the Ardouin Parkinson's Disease Behavioral Assessment (ECMP) scale at 11 weeks. Started Jan 2019; status: completed.
02
Drugs
acetylcysteine
03
Conditions
impulse control disorder (ICD)
Beyond the preview
Go deeper on NCT03146130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03146130.